GLP1R and atherosclerosis: For both drug classes, the effect on lowering the risk of MACE was restricted to approximately 14% in patients with established ASCVD (HR, 0.86; 95% CI, 0.82–0.90; P < 0.001), with nearly identical effects for finerenone (HR, 0.85; 95% CI, 0.77–0.95) and GLP1-RA (HR, 0.86; 95% CI, 0.82–0.90), whereas in the trials published to date, neither reduces the risk of MACE in patients without established ASCVD (HR, 0.93; 95% CI, 0.85–1.02; P = 0.12).